Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling

被引:89
作者
Vermeiren, H.
Van Craenenbroeck, E.
Alen, P.
Bacheler, L.
Picchio, G.
Lecocq, P.
机构
[1] Virco BVBA, B-2800 Mechelen, Belgium
[2] VircoLab Inc, Durham, NC USA
[3] VircoLab Inc, Bridgewater, NJ USA
关键词
linear regression; HIV-1; phenotype prediction;
D O I
10.1016/j.jviromet.2007.05.009
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Linear regression modeling on a database of HIV-1 genotypes and phenotypes was applied to predict the HIV-1 resistance phenotype from the viral genotype. In this approach, the phenotypic measurement is estimated as the weighted sum of the effects of individual mutations. Higher order interaction terms (mutation pairs) were included to account for synergistic and antagonistic effects between mutations. The most significant mutations and interactions identified by the linear regression models for 17 approved antiretroviral drugs are reported. Although linear regression modeling is a statistical data-driven technique focused on obtaining the best possible prediction, many of these mutations are also known resistance-associated mutations, indicating that the statistical models largely reflect well characterized biological phenomena. The performance of the models in predicting in vitro susceptibility phenotype and virologic response in treated patients is described. In addition to a high concordance with in vitro measured fold change, which was the primary aim of model design, the models per drug show good predictivity of therapy response for regimens including that drug, even in the absence of other clinically relevant factors such as background regimen. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 32 条
[1]  
BACHELER L, 2002, 6 INT C DRUG THER HI
[2]   A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy [J].
Baxter, JD ;
Mayers, DL ;
Wentworth, DN ;
Neaton, JD ;
Hoover, ML ;
Winters, MA ;
Mannheimer, SB ;
Thompson, MA ;
Abrams, DI ;
Brizz, BJ ;
Ioannidis, JPA ;
Merigan, TC .
AIDS, 2000, 14 (09) :F83-F93
[3]  
BIRKNER MD, 2005, BIOSTASTICS WORKING, V196
[4]  
CASTOR D, 2004, 15 INT AIDS C, V6
[5]   Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors [J].
Clark, Shauna A. ;
Shulman, Nancy S. ;
Bosch, Ronald J. ;
Mellors, John W. .
AIDS, 2006, 20 (07) :981-984
[6]   A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy [J].
Cohen, CJ ;
Hunt, S ;
Sension, M ;
Farthing, C ;
Conant, M ;
Jacobson, S ;
Nadler, J ;
Verbiest, W ;
Hertogs, K ;
Ames, M ;
Rinehart, AR ;
Graham, NM .
AIDS, 2002, 16 (04) :579-588
[7]   Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing [J].
De Luca, A ;
Perno, CF .
CURRENT OPINION IN INFECTIOUS DISEASES, 2003, 16 (06) :573-580
[8]  
Geretti Anna Maria, 2004, J HIV Ther, V9, P28
[9]  
Gupta S, 2006, ANTIVIR THER, V11, pS143
[10]   A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study [J].
Hales, Gillian ;
Birch, Chris ;
Crowe, Suzanne ;
Workman, Cassy ;
Hoy, Jennifer F. ;
Law, Matthew G. ;
Kelleher, Anthony D. ;
Lincoln, Douglas ;
Emery, Sean .
PLOS CLINICAL TRIALS, 2006, 1 (03)